Physician profile
Visha Dinesh
NPI 1124283916
$1,085.95
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $109 · 2021: $130 · 2022: $660.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.65 | 2021-2022 | |
| Janssen Biotech, INC. | $221.88 | 2022 | |
| Merck Sharp & Dohme LLC | $114.82 | 2019-2022 | |
| Amgen INC. | $98.05 | 2019-2022 | |
| Gilead Sciences, INC. | $74.08 | 2019-2020 | |
| Novo Nordisk INC | $65.68 | 2020-2021 | |
| Abbott Laboratories | $64.17 | 2021-2022 | |
| Pfizer INC. | $29.09 | 2022 | |
| Lilly USA, LLC | $28.57 | 2022 | |
| Ibsa Pharma INC. | $20.87 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.87 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.58 | 2022 | |
| Glaxosmithkline, LLC. | $16.98 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Visha Dinesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.